Background:
Radioimmunotherapy (rit) is a promising new modality for targeted, systemic delivery of radionuclides specifically to sites of androgen-independent metastatic prostate cancer. to be effective, rit requires an antibody with specificity for malignant cells and appropriate pharmacokinetics in the body.
Methods:
Specific binding of the l6 monoclonal antibody to prostate cancer cell lines or cell lysates was determined by enzyme-linked immunoabsorbent assay (elisa), solid-phase radioimmunoassay, and immunofluorescent staining. biodistribution, tumor uptake, and whole body and blood clearances of 125i-l6 were determined in nude mice bearing human prostate cancer xenografts.
Results:
The l6 monoclonal antibody showed strong binding to the lysates of pc3 and du145 prostate cancer cell lines, and 66% binding to live pc3 cells. the l6 antibody specifically targeted prostate cancer in pc3 and du145-tumored nude mice, where approximately 10% of the injected dose of 125i-l6 bound to prostate cancer. low-normal organ uptake was found, and the blood clearances were similar in each group of tumored mice.
Conclusions:
The l6 monoclonal antibody targets human prostate cancer xenografts in nude mice and has low-normal organ uptake. therefore, further study of the radiolabeled l6 monoclonal antibody for rit of prostate cancer is warranted.